illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Huons Global
Company logo

Huons Global | Sustainability Performance

https://huonsglobal.com/eng/home.php
Linkedin

A South Korean pharmaceutical and healthcare company producing medicines, medical devices, and wellness products.

1965

South Korea

1,001 - 5,000 employees

Pharmaceuticals

$500M - 1B in revenue

$25M - 100M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#9430
Overall
#122
in South Korea
#223
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusionsB-corp & CDP
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Seegene

South Korea, Hospital & Health Care, Biotechnology


Company logo
Shinpoong Pharm

South Korea, Hospital & Health Care, Pharmaceuticals


Company logo
Alteogen

South Korea, Hospital & Health Care, Biotechnology

Market cap

351.4T $, 2026▼100.2% YoY

Revenue

596.0M $, 2025▲4% YoY

R&D intensity

7.89% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

351.4T $, 2026▼100.2% YoY

Revenue

596.0M $, FY2025▲4% YoY

EBITDA

63.8M $, FY2025▼9.1% YoY

Operating margin

11% Industry: -24▲1.2% YoY

Revenue & EBITDA

$596.0MFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-23.4M 2024▲160.8% YoY

Capex

94.1M 2024▲40.4% YoY

Debt/equity ratio

0.2 Industry: 0▼NaN% YoY

R&D intensity

7.9%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

4.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.5

2023

0.6

2024

0.6

2025

NaN


Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

10%
Independent Directors

1 out of 10 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

CDP Scores


Climate Score

Not disclosed

Forests Score

Not disclosed

Water Score

Not disclosed

A

A-

B

B-

C

C-

D

D-

Powered by illuminem and GIST impact

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email